Anika Therapeutics Inc.

ANIK Healthcare Drug Manufacturers Specialty & Generic

Anika Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $112.8 million, down 5.91% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 189.3% and free cash flow grew 61.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

19.98 0.71 −3.43%
Market cap
$276.9M
P/E
0.0×
Fwd P/E
−20.0×
Dividend yield
—
F-score
6/9
Altman Z
3.13
Beneish M
−2.84
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
1.62 1.69 1.22 1.20
P/FCF ratio
347.01 0.00 27.77 108.60
P/Operating CF
(285.11) (40.49) 29.72 19.73
P/B ratio
1.42 1.47 0.96 0.92
Price to Tangible BV
1.53 1.58 1.03 0.99
EV/Sales
1.51 1.55 0.93 0.91
EV/EBITDA
354.70 0.00 0.00 0.00
EV/Operating CF
30.38 27.84 9.41 12.61
EV/FCF
323.14 (63.07) 21.22 82.17
Quick Ratio
3.05 3.19 3.71 4.20
Current Ratio
4.48 4.46 4.72 5.32
Net Debt/EBITDA
(8.61) 10.05 (29.27) 31.69
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.65 0.63 0.57 0.54
Operating CF/Net income
(0.21) 0.96 15.88 (2.95)
Capex/Depreciation
(0.96) (1.02) (0.49) (1.34)
Research and Development Expense of Revenue
22.51% 22.67% 21.07% 24.97%
Selling, General and Administrative Expense of Revenue
33.58% 60.02% 39.46% 42.68%
Intangible Assets out of Total Assets
0.05 0.05 0.05 0.05
Share Based Compensation of Revenue
5.62% 22.43% 8.03% 7.96%
Graham Net Nets
0.27 0.25 0.41 0.44
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(1.78%) (5.45%) (7.91%) (24.26%)
Free Cash Flow Yield
0.29% (1.46%) 3.60% 0.92%
Revenue per Share
2.45 2.19 2.14 1.93
Operating CF per Share
(0.05) (0.36) 0.32 0.48
Capex per Share
(0.11) (0.11) (0.05) (0.13)
Free Cash Flow per Share
(0.16) (0.46) 0.28 0.35
Cash per Share
2.88 3.03 4.01 4.02
Shareholders Equity per Share
10.30 9.90 10.01 10.18
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
10.30 9.90 10.01 10.18
Free Cash Flow
(2.13) (6.28) 3.99 4.98
Working Capital
77.04 72.60 81.45 82.50
Capital Expenditures
(1.45) (1.43) (0.65) (1.89)
Net Current Asset Value
53.00 48.08 56.55 58.96
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.04 0.05 0.02 0.07
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
26.51 23.88 23.64 25.27
Average Payables
5.50 5.81 5.83 5.77
Average Inventory
22.74 22.09 21.30 27.96
Average Assets
185.58 185.00 196.51 210.42
Average Common Equity
142.48 141.15 148.73 163.33

Fold the line items

Columns are period end dates